dlx4a Antibody

Frequently Asked Questions on DLX4 Antibody Applications in Academic Research

How to Validate DLX4 Antibody Specificity in Novel Experimental Models?

Methodological Approach:

• Perform knockout validation using CRISPR-Cas9 in target cell lines (e.g., HEK293) followed by Western blot (WB) to confirm loss of signal .

• Use peptide blocking: Pre-incubate antibody with immunogen peptide (e.g., residues 72–100 for ABIN657967 ) at 1:10 molar ratio for 1 hr. Compare blocked vs. unblocked WB signals.

• Validate across species using tissues with known DLX4 expression (e.g., human ccRCC vs. mouse embryonic palate ).

Key Data:

What Experimental Design Factors Are Critical When Selecting DLX4 Antibodies for Developmental Biology Studies?

Advanced Considerations:

• Epitope Location: Antibodies targeting the C-terminal (e.g., ABIN657967 ) may miss isoforms lacking this domain. Map epitopes to exons conserved across splice variants.

• Fixation Compatibility: For embryonic tissue IHC, test citrate vs. EDTA antigen retrieval using antibodies validated for formalin-fixed paraffin-embedding (FFPE) .

• Temporal Expression: Align antibody reactivity window with developmental stages (e.g., murine E12.5 palatal mesenchyme requires antibodies working in early organogenesis ).

How to Resolve Contradictory DLX4 Expression Data Between Cancer Studies?

Analytical Framework:

• Compare antibody clonality: Polyclonal (HPA059933 ) vs. monoclonal (1F11 clone ) may detect different epitopes.

• Quantify using orthogonal methods:

  • RNA-seq correlation (TCGA-KIRC R² ≥0.4 considered acceptable )

  • Multiplex IHC with RNAscope® validation

• Control for tumor heterogeneity via laser-capture microdissection of epithelial vs. stromal compartments .

Case Example:
In ccRCC, DLX4 mRNA upregulation (log2FC=2.1 ) may contrast with protein-level data due to:

• Post-translational modifications

• Stromal vs. tumor cell expression ratios

• Antibody cross-reactivity with DLX3/DLX5 paralogs

What Advanced Techniques Enable DLX4 Interaction Mapping in Transcriptional Networks?

Integrated Workflow:

• Co-IP/MS: Use crosslinkers (1% formaldehyde) with DLX4 antibodies coupled to magnetic beads (Dynabeads®). Identify partners like NF-κB subunits .

• CUT&RUN: Profile genome-wide binding using validated antibodies , comparing wild-type vs. DLX4-mutant cell lines.

• Luciferase Reporter Assays: Test DLX4 regulation of conserved elements (e.g., I5/6i enhancer ) with/without antibody-mediated blocking.

Critical Controls:

• Isotype-matched IgG for IP background

• Rescue experiments with HA-tagged DLX4

• siRNA knockdown efficiency ≥70%

How to Design Rigorous DLX4 Functional Studies in Disease Models?

Cancer Biology Protocol:

• Stratify xenograft models by DLX4 status (high vs. low via qPCR )

• Treat with pathway inhibitors (e.g., IL-1β antagonist Anakinra )

• Assess metastasis via intravital imaging (primary vs. peritoneal implants )

Developmental Studies:

• Electroporate DLX4 shRNAs into E10.5 murine palatal shelves

• Quantify BMP4 expression changes via smFISH

• Perform μCT analysis of craniofacial structures at E18.5

What Computational Tools Enhance DLX4 Antibody Data Interpretation?

Bioinformatics Pipeline:

• Spatial Deconvolution: Use ESTIMATE algorithm to adjust for immune infiltration in IHC quantification

• Isoform-Specific Analysis: Align RNA-seq reads to DLX4 splice variants (ENST00000369442.7 vs. ENST00000528743.1)

• Structural Modeling: Predict antibody-epitope interactions using AlphaFold2 (residues 72–100 accessibility score >0.8 )

How to Address Antibody Cross-Reactivity in DLX Family Members?

Validation Matrix:

Source: Epitope alignment from

What Are Emerging DLX4 Research Frontiers Requiring Antibody Innovation?

• Phase Separation Studies: Develop antibodies recognizing liquid-liquid phase separation states (test via optoDroplet assay)

• Single-Cell Proteomics: Optimize antibodies for CITE-seq (≥10 oligonucleotide tags/antibody)

• Post-Translational Modifications: Generate phospho-specific reagents (e.g., pSer82-DLX4)

How to Standardize DLX4 Quantification Across Multi-Institutional Studies?

Consensus Guidelines:

• Reference Standard: Distribute aliquots of DLX4-overexpressing cell lysate (e.g., HEK293-DLX4 )

• Normalization: Express data as % positive nuclei relative to internal controls (β-catenin membrane staining)

• Digital Pathology: Adopt QuPath analysis with pre-trained DLX4 classifier (AUC ≥0.9 )

What Are Key Limitations of Current DLX4 Antibodies in Mechanistic Studies?

Critical Evaluation:

• Isoform Discrimination: Most commercial antibodies (e.g., ABIN657967 ) cannot differentiate between BP1 and DLX4 isoforms

• Dynamic Range: Limited detection of nuclear vs. cytoplasmic localization changes

• Multiplex Compatibility: Spectral overlap in 7-color IHC panels requiring custom conjugations

Innovation Opportunities:

• Nanobody-based intrabodies for live-cell imaging

• Proximity ligation assays for interaction quantification

• CRISPR-engineered epitope tags (HiBiT knock-in)